STAT June 20, 2024
Jason Mast

Gilead said Thursday that twice-a-year injections of a new antiviral drug, called lenacapavir, completely protected cisgender women from contracting HIV in a large Phase 3 trial.

In the study, none of the 2,134 women who received lenacapavir contracted HIV. By comparison, 16 of the 1,068 women who received the long-running daily pill...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma, Pharma / Biotech, Trends
Navigating Complex Regulatory Landscapes in the Biopharmaceutical Industry
How Life Sciences Can Drive Innovation And Sustainability In Returns Management
10X Genomics at JPM: New Products, New Sales Team, New Markets
Enhancing Target Screening with CRISPR Libraries: Revolutionizing Drug Discovery and Functional Genomics
Daiichi Sankyo Announces New CEO

Share This Article